ADB-HEXINACA
![]()  | |
| Legal status | |
|---|---|
| Legal status | 
  | 
| Identifiers | |
IUPAC name 
  | |
| PubChem CID | |
| ChemSpider | |
| Chemical and physical data | |
| Formula | C20H30N4O2 | 
| Molar mass | 358.486 g·mol−1 | 
| 3D model (JSmol) | |
SMILES 
  | |
InChI 
  | |
ADB-HEXINACA (also known as ADB-HINACA and ADMB-HEXINACA) is a cannabinoid designer drug that has been found as an ingredient in some synthetic cannabis products, first appearing in early 2021. It is a longer chain homologue of previously encountered synthetic cannabinoid compounds such as ADB-BUTINACA and ADB-PINACA.[1][2] The pharmacology of ADB-HEXINACA and numerous analogues at CB1 and CB2 receptors has been reported.[3]
See also
References
- ↑ Kronstrand R, Norman C, Vikingsson S, Biemans A, Valencia Crespo B, Edwards D, et al. (November 2021). "The metabolism of the synthetic cannabinoids ADB-BUTINACA and ADB-4en-PINACA and their detection in forensic toxicology casework and infused papers seized in prisons". Drug Testing and Analysis. 14 (4): 634–652. doi:10.1002/dta.3203. PMID 34811926. S2CID 244490343.
 - ↑ Gilbert N, Costello A, Ellison JR, Khan U, Knight M, Linnell MJ, et al. (December 2021). "Synthesis, characterisation, detection and quantification of a novel hexyl-substituted synthetic cannabinoid receptor agonist: (S)-N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-hexyl-1H-indazole-3-carboxamide (ADB-HINACA)" (PDF). Forensic Chemistry. 26: 100354. doi:10.1016/j.forc.2021.100354.
 - ↑ Sparkes E, Timmerman A, Markham JW, Boyd R, Gordon R, Walker KA, et al. (April 2024). "Synthesis and Functional Evaluation of Synthetic Cannabinoid Receptor Agonists Related to ADB-HEXINACA". ACS Chemical Neuroscience. doi:10.1021/acschemneuro.3c00818.
 
    This article is issued from Wmcloud. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.
